Pipeline

Pipeline

CV Sciences operates two distinct divisions: pharmaceuticals and consumer products. These divisions are supported by our medical and scientific advisory board, and state-of-the art production facilities.

Pipeline

CV Sciences is in development of CBD-based potential FDA approved drugs. In December 2015, CV Sciences acquired CanX Inc., a pre-clinical drug development company focused on significant unmet medical needs. The initial drug candidate (CVSI-007) is a chewing gum containing nicotine and synthetic CBD to support cessation of smokeless tobacco use and addiction.
INDICATION PRODUCT
Smokeless Tobacco Cessation CVSI-007
PRECLINICAL PHASE 1 PHASE 2 PHASE 3
phasebar